Stoke Therapeutics, Inc. (STOK) — SEC Financial Statements & Analysis

Stoke Therapeutics, Inc. (STOK) is a pharmaceutical preparations company, incorporated in DE. Stoke Therapeutics, Inc. trades on Nasdaq as: STOK. Stoke Therapeutics, Inc. (STOK)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03. Based on that filing, Stoke Therapeutics, Inc. carries a market cap of $2.16B, a P/E ratio of -10.39x, a P/B ratio of 6.25x, a P/S ratio of 78.30x, an enterprise value of $2.05B, and an EV/EBITDA multiple of -9.25x. On profitability, it posts an operating margin of -809.69%, a net margin of -753.60%, a Return on Equity (ROE) of -61.10%, a Return on Assets (ROA) of -53.41%, and a Return on Invested Capital (ROIC) of -93.76%. Per share, it reports EPS of $-3.15, diluted EPS of $-3.15, free cash flow per share of $-2.74, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -86.20% year-over-year, net income growth of -496.12% year-over-year, and EPS growth of -450.14% year-over-year. On the balance sheet, it maintains a current ratio of 7.69x, a quick ratio of 7.34x, working capital of $280.61M, a debt-to-equity ratio of 0.14x, a debt ratio of 0.12, an interest coverage ratio of -15.98x, free cash flow of $-180.68M (TTM), and net debt of $-110.00M. Figures sourced from SEC EDGAR.

Market Cap

$2.16B

P/E TTM

-10.39x

EPS TTM

$-3.15

P/B TTM

6.25x

ROE TTM

-61.10%

ROA TTM

-53.41%

Debt To Equity

0.14x

Free Cash Flow TTM

$-180.68M

Net Revenue TTM Growth 1Y

-86.20%

Data as of 2026-06-30 · Source: SEC EDGAR